Current Report Filing (8-k)
October 01 2014 - 10:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 1, 2014
SPHERIX INCORPORATED
(Exact Name of Registrant as Specified in
Charter)
Delaware |
|
0-5576 |
|
52-0849320 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
6430 Rockledge Drive, Suite 503
Bethesda, MD |
|
|
|
20817 |
(Address of principal executive
offices) |
|
|
|
(Zip Code) |
Registrant’s
telephone number, including area code: (703) 992-9260
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On October 1, 2014,
Spherix Incorporated issued the press release attached hereto as Exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
The exhibit listed
in the following Exhibit Index is furnished as part of this Current Report on Form 8-K.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release dated October 1, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 1, 2014
|
|
SPHERIX INCORPORATED |
|
|
|
|
By: |
/s/ Anthony Hayes |
|
|
Name: Anthony Hayes |
|
|
Title: Chief Executive Officer |
|
|
|
Exhibit 99.1
Markman Hearing Date for VTech and Uniden
Litigation Now Set for November 10, 2014
- Efforts to Monetize Patent Portfolio
Continue to Move Forward -
BETHESDA, MD, October 1, 2014 /PRNewswire/
— Spherix Incorporated (Nasdaq: SPEX) — an intellectual property development company committed to the
fostering and monetization of intellectual property, announced today that the Markman hearing for Spherix’s litigation against
VTech and Uniden in the U.S. District Court for the Northern District of Texas has been rescheduled for November 10, 2014. This
hearing was originally scheduled for October 2, 2014. The Court Order setting the Markman date was received after the close of
business on September 29, 2014. As previously indicated, all litigation dates are subject to change at any time.
Anthony Hayes, Chief Executive Officer
of Spherix, stated, “changes to the litigation schedule are often altered, based on requests from the court or from the parties.
It’s a normal part of the litigation cycle.”
Mr. Hayes continued, “Each case is
unique, and there can be no assurances in this case, but Markman hearings typically represent an inflection point in the litigation.
While this process can still take a few months to resolve, normally a Markman hearing can give the parties an understanding of
how key terms will be construed. It therefore provides each side some guidance. The timing of the ruling by the Court after the
Markman hearing is issued at the Court’s discretion.”
About Spherix
Spherix Incorporated was launched in 1967
as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market.
Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,”
“might,” “will,” “should,” “believe,” “expect,” “anticipate,”
“estimate,” “continue,” “predict,” “forecast,” “project,” “plan,”
“intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking
statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on
any such forward-looking statements, which are based on information available to us on the date of this release. These forward
looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including
without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the “SEC”),
not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different.
The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events
or otherwise, except as required by law.
Contact:
Investor Relations: |
Hayden IR |
|
Brett Mass, Managing Partner |
|
Phone: (646) 536-7331 |
|
Email: brett@haydenir.com |
|
www.haydenir.com |
|
|
Spherix: |
Phone: (703) 992-9325 |
|
Email: info@spherix.com |
|
www.spherix.com |
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Sep 2023 to Sep 2024